These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 2121921

  • 1. Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation.
    Frist WH, Merrill WH, Eastburn TE, Atkinson JB, Stewart JR, Hammon JW, Bender JW.
    J Heart Transplant; 1990; 9(5):489-94. PubMed ID: 2121921
    [Abstract] [Full Text] [Related]

  • 2. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
    Kirklin JK, Bourge RC, White-Williams C, Naftel DC, Thomas FT, Thomas JM, Phillips MG.
    J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
    [Abstract] [Full Text] [Related]

  • 3. Comparative trial of immunoprophylaxis with RATG versus OKT3.
    Griffith BP, Kormos RL, Armitage JM, Dummer JS, Hardesty RL.
    J Heart Transplant; 1990 Apr; 9(3 Pt 2):301-5. PubMed ID: 2113093
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Prophylactic OKT3 used as induction therapy for heart transplantation.
    Starnes VA, Oyer PE, Stinson EB, Dein JR, Shumway NE.
    Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
    Renlund DG, O'Connell JB, Gilbert EM, Hammond ME, Burton NA, Jones KW, Karwande SV, Doty DB, Menlove RL, Herrick CM.
    Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
    [Abstract] [Full Text] [Related]

  • 9. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
    Barr ML, Sanchez JA, Seche LA, Schulman LL, Smith CR, Rose EA.
    Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
    [Abstract] [Full Text] [Related]

  • 10. Rabbit antithymocyte globulin. A 10-year experience in cardiac transplantation.
    Copeland JG, Icenogle TB, Williams RJ, Rosado LJ, Butman SM, Vasu MA, Sethi GK, McDonald AN, Klees E, Rhenman MJ.
    J Thorac Cardiovasc Surg; 1990 May; 99(5):852-60. PubMed ID: 2329823
    [Abstract] [Full Text] [Related]

  • 11. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
    Hegewald MG, O'Connell JB, Renlund DG, Lee HR, Burton NA, Karwande SV, Jones KW, Lassetter JE, Bristow MR.
    J Heart Transplant; 1989 May; 8(4):303-9; discussion 309-10. PubMed ID: 2504897
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Heart transplantation in females.
    Esmore D, Keogh A, Spratt P, Jones B, Chang V.
    J Heart Lung Transplant; 1991 May; 10(3):335-41. PubMed ID: 1854761
    [Abstract] [Full Text] [Related]

  • 14. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
    Costanzo-Nordin MR, O'Sullivan EJ, Hubbell EA, Zucker MJ, Pifarre R, McManus BM, Winters GL, Scanlon PJ, Robinson JA.
    J Heart Transplant; 1989 May; 8(4):288-95. PubMed ID: 2504895
    [Abstract] [Full Text] [Related]

  • 15. A prospective randomized controlled trial of initial immunosuppression with ALG versus OKT3 in recipients of cardiac allografts.
    Menkis AH, Powell AM, Novick RJ, McKenzie FN, Kostuk WJ, Pflugfelder PW, Brown JE, Rochon J, Chow LH, Stiller C.
    J Heart Lung Transplant; 1992 May; 11(3 Pt 1):569-76. PubMed ID: 1610866
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Selective use of OKT3 in heart transplantation with the use of risk factor analysis.
    Macris MP, Van Buren CT, Sweeney MS, Frazier OH, Duncan JM.
    J Heart Transplant; 1989 May; 8(4):296-302. PubMed ID: 2504896
    [Abstract] [Full Text] [Related]

  • 18. Monoclonal versus polyclonal antibody therapy for prophylaxis against rejection after heart transplantation.
    Kormos RL, Herlan DB, Armitage JM, Stein K, Kaufman C, Zeevi A, Duquesnoy R, Hardesty RL, Griffith BP.
    J Heart Transplant; 1990 May; 9(1):1-9, discussion 9-10. PubMed ID: 2107288
    [Abstract] [Full Text] [Related]

  • 19. Reversal of steroid- and antithymocyte globulin-resistant acute rejection crises in renal transplantation with monoclonal antibody (OKT3).
    Prieto C, Rodriguez-Paternina E, Andrés A, Morales JM, Farias J, Montoyo C, Regueiro JR, Rodicio JL.
    Transplant Proc; 1990 Aug; 22(4):1753-4. PubMed ID: 2117798
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.